-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Announced Topline Results From SURPASS-CVOT Head-to-head Phase 3 Trial Comparing Mounjaro (Tirzepatide) To Trulicity (Dulaglutide), Mounjaro Achieved The Primary Objective By Demonstrating A Non-inferior Rate Of Major Adverse Cardiovascular Events, Including Cardiovascular Death, Heart Attack Or Stroke Vs. Trulicity

Benzinga·07/31/2025 10:47:50
Listen to the news
  • Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight
  • In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits
  • Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile